麻豆传媒

For three decades, Mr. Baldridge has litigated disputes concerning antitrust, intellectual property, false advertising (both private and FTC regulatory matters), unfair competition, First Amendment and publishers' rights, franchise agreements, toxic torts, securities, commercial lending, commercial real estate and general business issues. A first chair trial lawyer, he has tried to verdict numerous complex matters. Most recently he secured a victory for a generic drug maker in the first test of what limits may be placed on reverse payment antitrust deals in the wake of the U.S. Supreme Court's decision in FTC v. Actavis. (In Re: Nexium (Esomeprazole) Antitrust Litigation).

Mr. Baldridge has been recognized by a number of publications, including the National Law Journal, Law360, and Global Competition Review, as an "elite" trial lawyer and competition law "MVP" and is a "Recognized Practitioner" in the General Commercial area of the 2014 and 2015 editions of Chambers USA. He has just been selected as a 鈥淪uper Lawyer鈥� in the Washington DC edition of Super Lawyers for 2018.

Mr. Baldridge is Chair of Venable's Washington Litigation Group encompassing the Washington, DC and Virginia offices. He also serves as General Counsel of duPont Publishing which distributes magazines under the duPont Registry brand in the United States and 54 countries.